Discontinued — last reported Q4 '25
Charges associated with convertible senior notes
Over 3 years (FY 2022 to FY 2025), Charges associated with convertible senior notes shows a downward trend with a -100.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase reflects higher financing costs or specific accounting adjustments related to debt structure, which can impact reported net income.
Detailed definition
These are non-cash charges or adjustments related to the accounting treatment of convertible debt instruments. They refl...
Peer comparison
Specific to companies with complex capital structures; peers with similar debt profiles will report comparable adjustments.
operating_charges_associated_with_convertible_senior_notesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.50M | $17.50M | $17.50M | $17.50M | $0.00 | $0.00 | $0.00 | $0.00 | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | — | -44.0% | -100.0% | — | — | — | — | — |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | -100.0% | -100.0% | — | — |
Business Segments
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $88.70M | $49.70M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Charges associated with convertible senior notes at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's charges associated with convertible senior notes?
- Neurocrine Biosciences (NBIX) reported charges associated with convertible senior notes of $0.00 in Q4 2025.
- What is the long-term trend for Neurocrine Biosciences's charges associated with convertible senior notes?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's charges associated with convertible senior notes has grown at a -100.0% compound annual growth rate (CAGR), from $70.00M to $0.00.
- What does charges associated with convertible senior notes mean?
- Non-cash accounting adjustments related to the company's convertible debt financing.